Clinical significance of serum CD44 measurement in malignant lymphoma

Kurume Medical Journal

Volumn 48, Issue 1, 2001, Pages 65-69

  Fukuda, Yumi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD44; Malignant lymphoma; Soluble CD44std; Soluble CD44v6; Soluble interleukin 2 receptor

Indexed keywords

HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR;

ARTICLE; BLOOD; HUMAN; NONHODGKIN LYMPHOMA;

ANTIGENS, CD44; HUMANS; LYMPHOMA, NON-HODGKIN; RECEPTORS, INTERLEUKIN-2;

EID: 0035222791     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.48.65     Document Type: Article

References (22)

1. Senni T. Risk factor of malignant lymphoma. Annual Review Hematology 1995:223-233. (in Japanese)
2. Sorimachi N, and Miyasaka M. Adhesion molecules in immune system -A novel ligando for CD44. Experimental Medicine 1994; 12:162-168. (in Japanese)
3. Lesley J, Hyman R, and Kincade PW. CD44 and its interaction with extracellular matrix. Advances in Immunology 1993; 54:277-335.
4. Sorimachi N. CD44 and secletins -Recent advance and perspectives. 1996; 14:53-60. (in Japanese)
5. Gunthert U, Hofmann M, Rudy W, Reber S, Zoiier M et al. A new variant of Glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65:13-24.
6. Horst E, Meijer C, Radaszkiewiczt JM, Ossekoppele GJ, van Kriken HJM et al. Adhesion molecules in the prognosis of diffuse large-cell lymphoma. Expressin of a lymphocyte homing receptor (CD44), LFA-1 (CD1 1a/18), and ICAM-1 (CD54). Leukemia 1990; 4:595-599.
7. Jalkanen S, Joenssu H, Soderstrom KO, and Klemi P. Lymphocyte homing and clinical behavior of non-Hodgkin's lymphoma. J Clin Invest 1991; 87:1835-1840.
8. Sy MS, Guo YJ, and Stamenkovic I. Distinct effects of two CD44 isoforms on tumor growth in vivo. J Exp Med 1991; 174:859-866.
9. Terpe HJ, Koopmann R, Imhof B, and Guntert U. Expresson of intergrins and CD44 isoforms in non-Hodgkin's lymphomas:CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. Journal of Pathology 1994; 174:89-100.
10. Takeuchi H, and Hirashima K. Leukemia: malignant lymphoma. Common Disease Serise 1993; 243-254. (in Japanese)
11. Sorimachi N. CD44 and its ligands. Biotherapy 1996; 10:565-573. (in Japanese)
12. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S et al. Participation in normal immune responses of metastasis -Inducing splice variant of CD44. Science 1992; 257:682-685.
13. Yasuda N, Lai PK, Stephen H, Kung PC, Hinuma Y et al. Soluble interleukin2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 1988; 171:1021-1026.
14. Rubin LA, and Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Annalis of Internal Medicine 1990; 113:619-627.
15. Pui CH. Serum interleukin-2 receptor: Clinical and biological implications. Leukemia 1989; 3:323-327.
16. Kohda K, Tateda I, Nakamura T, Matsumoto S, Nakazawa O et al. Clinical significance of serum soluble interleukin-2 receptor levels in non-Hodgkin's lymphoma. Japanese Journal of Cancer Clinics 1994; 31:1213-1218. (in Japanese)
17. Wolf R, and Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis and Rheumatism 1988; 31:729-735.
18. Setoyama Y, Imai J, Ishikawa T, Sakaida H, Takaori A et al. Usefulness of the measurement of serum soluble IL-2 receptor α chain levels in clinical monitoring of non-Hodgkin lymphoma. The Japanese Journal of Clinical Pathology 1994; 42:834-842.(in Japanese)
19. Ristamaki R, Joensuu H, Salmi M, and Jalkanen S. Serum CD44 in malignant lymphoma; An association with treatment response. Blood 1994; 84:238-243.
20. Kwak LW, Wilson M, Weiss LM, Dogett R, Dorfman RF et al. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas. The Stanford experience. Journal of Clinical Oncology 1991; 9:1426-1431.
21. Coiffer B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C et al. Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: A prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Annals of Oncology 1990; 1:45-50.
22. Slymen DJ, Miller TP, Lippman SM, Spier CM, Kerrigan DP et al. Immunobiologic factors predictive of clinical outcome in diffuse large cell lymphoma. Journal of Clinical Oncology 1990; 8:986-993.